 Shares of a clinical-stage biopharmaceutical company are falling in after-hours trading Tuesday after the company shared an update. What Happened: Cortexyme Inc NASDAQ: CRTX reported Phase 23 GAIN trial data for its Alzheimers disease trial Tuesday. 